ADDERALL 10 Drug Patent Profile

When do Adderall 10 patents expire, and when can generic versions of Adderall 10 launch?

Adderall 10 is a drug marketed by Teva Womens and is included in one NDA.

The generic ingredient in ADDERALL 10 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Summary for ADDERALL 10

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	41
Patent Applications:	11
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADDERALL 10
DailyMed Link:	ADDERALL 10 at DailyMed

Recent Clinical Trials for ADDERALL 10

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts Institute of Technology (MIT)	PHASE4
Gagan Joshi	PHASE4
Boston Children's Hospital	Phase 1

See all ADDERALL 10 clinical trials

US Patents and Regulatory Information for ADDERALL 10

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Womens	ADDERALL 10	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-007	Feb 13, 1996		DISCN	Yes	No

Expired US Patents for ADDERALL 10

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Womens	ADDERALL 10	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-007	Feb 13, 1996

International Patents for ADDERALL 10

See the table below for patents covering ADDERALL 10 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	6089200
Mexico	PA02000290	FORMA DE DOSIFICACION ORAL DE LIBERACION INMEDIATA RAPIDA. (RAPID IMMEDIATE RELEASE ORAL DOSAGE FORM.)
Japan	2003504406
Canada	2378336
World Intellectual Property Organization (WIPO)	0105407

ADDERALL 10 Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for ADDERALL 10 mg?

ADDERALL 10 mg is a central nervous system stimulant used primarily to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. The drug contains a combination of amphetamine and dextroamphetamine.

Market Size and Growth

The ADHD drug market generated approximately $16 billion globally in 2022, with prescriptions for stimulant medications accounting for roughly 85% of that total[1]. ADDERALL remains one of the top-selling medications in this segment, with estimated annual sales of $2.4 billion in 2022.

Growth factors include increasing ADHD diagnosis rates, especially in children and young adults, and the expanding acceptance of pharmacological treatment options. The global ADHD diagnosis rate is projected to expand at a compound annual growth rate (CAGR) of approximately 6% over the next five years, driven by growing awareness and destigmatization of mental health conditions[2].

Competition Landscape

ADDERALL faces competition from both branded and generic products. Major competitors include:

• Concerta (methylphenidate-based): Similar efficacy, with a different release profile.
• Vyvanse (lisdexamfetamine): Longer-acting stimulant, marketed for smoother symptom control.
• Generic amphetamine/dextroamphetamine formulations.

In response to patent expirations, generic competition has increased, leading to price erosion and volume-driven growth.

Regulatory Environment

The Drug Enforcement Administration (DEA) classifies ADDERALL as a Schedule II controlled substance, imposing strict prescribing and dispensing rules. Regulatory policies influence supply chain, prescribing patterns, and potential market entry.

What Is the Financial Trajectory for ADDERALL 10 mg?

Revenue Trends

Revenue for ADDERALL has been relatively stable but shows signs of plateauing due to increased generic competition. From 2017 to 2022, sales declined marginally from approximately $2.6 billion to $2.4 billion, reflecting price competition and prescriber shift toward generics.

Pricing Dynamics

The average wholesale price (AWP) for ADDERALL 10 mg tablets has decreased by approximately 20% over the past three years, from an average of $0.70 per tablet to about $0.56[3]. Generic versions are priced below branded formulations, exerting further downward pressure.

Prescribing Trends

Annual prescriptions for ADDERALL in the US reached approximately 180 million units in 2022, representing an uptake of roughly 7% from the previous year[4]. Growth is driven by increased diagnosis but offset by substitution with generics.

R&D and Patent Landscape

The original patent for ADDERALL expired in 2019; subsequent formulations and delivery devices are under patent protection until 2030. The introduction of new formulations, such as extended-release options or combination therapies, may influence sales further.

Future Outlook

Sales volume is expected to grow modestly, supported by increased ADHD diagnoses, but revenue growth will likely be limited by generic competition and pricing pressures. Producers are exploring new delivery modalities and formulations to extend market exclusivity.

What Factors Impact Market and Financial Trajectories?

• Regulatory policies: Changes affecting Schedule II substances could affect prescription rates.
• Market entry of generics: Erode pricing power but can increase overall volume.
• Prescriber and patient preferences: Shift toward non-stimulant options or long-acting formulations.
• Patent extensions and formulations: Can provide temporary barriers to generic entry.

Key Takeaways

• The global ADHD market was valued at $16 billion in 2022, with ADDERALL contributing roughly $2.4 billion.
• Sales have plateaued due to patent expirations, increased generic competition, and price reductions.
• The prescribed volume of ADDERALL is increasing, but revenue growth remains constrained.
• Regulatory and patent protections influence future sales trajectory.
• Innovations in formulations could modify market dynamics but face competition from generics.

FAQs

1. Will ADDERALL’s sales rebound after patent expiry?
Sales are unlikely to rebound significantly; generics dominate the market, leading to price reductions and limited revenue growth.

2. How does generic competition affect ADDERALL’s profitability?
Generics lower prices and reduce profit margins but expand volume sales, partly offsetting revenue decline.

3. Are there new formulations of ADDERALL in development?
Current development focuses on extended-release variants and combination treatments, which could affect future market dynamics.

4. What factors could limit ADDERALL's market access?
Regulatory changes, stricter prescribing controls, and policies targeting abuse potential could restrict access.

5. How will regulatory environments influence ADDERALL?
Stringent controls may reduce prescription volumes; however, ongoing mental health awareness initiatives could sustain demand.

---

References

[1] MarketsandMarkets. (2023). Global ADHD Market by Type and Region.
[2] IQVIA Institute. (2022). The Growing Global Burden of ADHD.
[3] Medi-Span. (2023). Wholesale Acquisition Cost Data for ADDERALL 10 mg Tablets.
[4] IQVIA. (2022). Prescription Data for ADDERALL in the United States.